Springworks Therapeutics, Inc. (SWTX)
| Market Cap | 3.83B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -73.06M |
| Shares Out | 42.15M |
| EPS (ttm) | -13.84 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 21 |
| Last Price | $81.03 |
| Previous Close | $78.94 |
| Change ($) | 2.09 |
| Change (%) | 2.65% |
| Day's Open | 79.00 |
| Day's Range | 76.02 - 84.21 |
| Day's Volume | 189,722 |
| 52-Week Range | 20.44 - 84.21 |
Among the public companies that made the BioSpace list of the top up and coming life sciences firms in 2019 and 2020, the majority have seen gains in their share prices. Given this metric, inv...
STAMFORD, Conn., Jan. 05, 2021 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...
STAMFORD, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...
STAMFORD, Conn., Nov. 24, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...
SpringWorks Therapeutics Reports Third Quarter 2020 Financial Results and Recent Business Highlights
- Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors -
DUBLIN and STAMFORD, Conn., Oct. 26, 2020 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) ("SpringWorks") today announced that Jazz Ph...
STAMFORD, Conn., Oct. 13, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...
SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 10% on the day, amid huge volumes.
STAMFORD, Conn., Oct. 07, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...
STAMFORD, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for p...
Fifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalities Fifth industry collaboration to evaluate nirogacestat as a BCMA potentiator across modalities
STAMFORD, Conn., Sept. 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines fo...
STAMFORD, Conn., Sept. 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines fo...
Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities Third collaboration to evaluate nirogacestat in combination with BCMA therapies across modalities
– Enrollment Complete in the Phase 3 DeFi Trial of Nirogacestat in Adult Patients with Desmoid Tumors -
STAMFORD, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
STAMFORD, Conn., July 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
Preclinical data presented at the American Association for Cancer Research 2020 Virtual Annual Meeting II
STAMFORD, Conn., June 22, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
SpringWorks Therapeutics (SWTX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
STAMFORD, Conn., June 02, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
STAMFORD, Conn., May 26, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for ...
SpringWorks Therapeutics Reports First Quarter 2020 Financial Results and Recent Business Highlights
- Announced Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Nirogacestat, Extending Patent Protection into 2039 -
SpringWorks Therapeutics: View Ahead Of 2020 Catalysts
STAMFORD, Conn., March 18, 2020 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX) announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. P...
SOUTH SAN FRANCISCO, Calif. and STAMFORD, Conn., Jan. 13, 2020 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the developme...
The stock climbed after investors saw encouraging signs from a similar program.
STAMFORD, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
STAMFORD, Conn., Oct. 24, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (NASDAQ: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for...
STAMFORD, Conn., Sept. 24, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines fo...
STAMFORD, Conn., Sept. 17, 2019 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines fo...
Springworks Therapeutics, Inc. (NASDAQ: SWTX) made its public debut Friday morning, opening at $24.50 after being priced between $16 and $18 per share.
About SWTX
SpringWorks Therapeutics, a clinical-stage biopharmaceutical company, acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III clinical trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase IIb clinical trial for the treatment of neurofibromatosis type 1-associated plexiform neu... [Read more...]
| Industry Biotechnology | IPO Date Sep 13, 2019 |
| CEO Saqib Islam | Employees 71 |
| Stock Exchange NASDAQ | Ticker Symbol SWTX |
Analyst Forecasts
According to 6 analysts, the average rating for SWTX stock is "Buy." The 12-month stock price forecast is 86.00, which is an increase of 6.13% from the latest price.